ERBB2 and breast cancer: Conversely, following stratification by Her2−enriched vs. luminal B (Her2+) BC patients, in 35 patients in the luminal B subgroup, significantly higher pCR rates were observed in patients with lower TAZ expression (82% vs. 44% pCR rates, p = 0.035).